LY 3321367

Drug Profile

LY 3321367

Alternative Names: LY3321367

Latest Information Update: 14 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class Antibodies; Antineoplastics
  • Mechanism of Action HAVCR2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 19 Apr 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT03099109)
  • 19 Apr 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT03099109)
  • 10 Apr 2017 Eli Lilly plans a phase I trial for Solid tumours (Monotherapy, Combination therapy, Second-line therapy or greater) in USA, South Korea, Spain (IV) (NCT03099109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top